ArticleHealthcare (Basel, Switzerland)2022
Radiomics and Molecular Classification in Endometrial Cancer (The ROME Study): A Step Forward to a Simplified Precision Medicine.
Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Predictive models for lymph node metastasis in endometrial cancer: A systematic review and bibliometric analysis.Women's health (London, England)Pooled it
- Trial
- Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients.Journal of gynecologic oncology · 2023Trial
- Article
- Novel transcriptomic alterations in poorly differentiated endometrial carcinomas: evidence from South African women.Frontiers in oncology · 2026Article
- Article
- Missing a chance to prevent: disparities in completion of genetic evaluation in high-risk patients with endometrial cancer.Journal of gynecologic oncology · 2025Article
- Ultrasound in endometrial cancer: evaluating the impact of pre-surgical staging.Oncology reviews · 2025Review
- Amide proton transfer-weighted imaging combined with multiple models diffusion-weighted imaging of endometrial cancer: correlations between multi-modal MRI parameters and HIF-1α expression.Frontiers in oncology · 2025Article
- The value of multi-sequence magnetic resonance imaging and whole-tumor apparent diffusion coefficient histogram analysis in differentiating p53 abnormal from non-p53 abnormal endometrial carcinoma.Frontiers in oncology · 2025Article
- Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.Journal of gynecologic oncology · 2024Article
- Multimodal MRI-based radiomics models for the preoperative prediction of lymphovascular space invasion of endometrial carcinoma.BMC medical imaging · 2024Article
- Pyroptosis-associated genes and tumor immune response in endometrial cancer.Discover oncology · 2024Article
- A case report and literature review: A 19-year-old with endometrial carcinoma treated with medroxyprogesterone acetate. Importance of the medical interview and endometrial examination.Clinical case reports · 2024Article
- A prediction model based on deep learning and radiomics features of DWI for the assessment of microsatellite instability in endometrial cancer.Cancer medicine · 2024Article
- Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohort.BMC cancer · 2024Article
- Multiparameter MRI-based radiomics analysis for preoperative prediction of type II endometrial cancer.Heliyon · 2024Article
- FIGO 2023 endometrial staging: a leap of faith into the new "prognostic based' rather than "anatomical based" staging-too fast too furious??Journal of cancer research and clinical oncology · 2024Article
- Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.Journal of gynecologic oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular/genomic profiling is the most accurate method to assess prognosis of endometrial cancer patients. Radiomic profiling allows for the extraction of mineable high-dimensional data from clinical radiological images, thus providing noteworthy information regarding tumor tissues. Interestingly, the adoption of radiomics shows important results for screening, diagnosis and prognosis, across various radiological systems and oncologic specialties. The central hypothesis of the prospective trial is that combining radiomic features with molecular features might allow for the identification of various classes of risks for endometrial cancer, e.g., predicting unfavorable molecular/genomic profiling. The rationale for the proposed research is that once validated, radiomics applied to ultrasonographic images would be an effective, innovative and inexpensive method for tailoring operative and postoperative treatment modalities in endometrial cancer. Patients with newly diagnosed endometrial cancer will have ultrasonographic evaluation and radiomic analysis of the ultrasonographic images. We will correlate radiomic features with molecular/genomic profiling to classify prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.